Nagasaka Y, Kaku K, Nakamura K, Kaneko T
Department of Biochemistry, Yamaguchi University School of Medicine, Japan.
Biochem Pharmacol. 1995 Sep 28;50(7):1109-11. doi: 10.1016/0006-2952(95)00235-r.
Several lines of evidence have revealed that the oxidative modification of low-density lipoprotein (LDL) is probably associated with the genesis of the atherosclerotic region. CS-045 is a new (thiazolidine) class of oral hypoglycemic agent which has a hindered phenol in the side chain (an analogue of alpha-tocopherol). The present results indicate that CS-045 had a relatively high antioxidative potency in inhibiting the lipid peroxidation of human plasma LDL in vitro induced by 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) compared with that of alpha-tocopherol. These findings suggest that CS-045 may be useful in preventing the progression of atherosclerosis in diabetic patients.
多项证据表明，低密度脂蛋白（LDL）的氧化修饰可能与动脉粥样硬化区域的形成有关。CS - 045是一种新型（噻唑烷类）口服降糖药，其侧链含有受阻酚（α - 生育酚的类似物）。目前的结果表明，与α - 生育酚相比，CS - 045在体外抑制2,2'-偶氮二（2 - 脒基丙烷）二盐酸盐（AAPH）诱导的人血浆LDL脂质过氧化方面具有相对较高的抗氧化能力。这些发现表明，CS - 045可能有助于预防糖尿病患者动脉粥样硬化的进展。
